Inactivation of LATS1 and LATS2 would be associated with more aggressive tumours, and with a poorer prognosis [11], with the exception of oligodendrogliomas, for which hypermethylation of the LATS2 promoter predicts a better survival, as observed in CRC [48]. The gene discussed is LATS2; the disease is neoplasm.